無料プレビュー

ANI Pharmaceuticals, Inc. (ANIP) · NASDAQ

プロフィール

ANI Pharmaceuticals is a diversified biopharmaceutical company that develops, manufactures, and commercializes therapeutics through three business segments: Rare Disease, Brands, and Generics. Its Rare Disease portfolio includes Cortrophin Gel for autoimmune disorders and the Retina Franchise (ILUVIEN and YUTIQ) for ophthalmologic conditions acquired via Alimera Sciences in 2024. The Brands segment comprises 12+ branded products including Inderal, Lithobid, and Vancocin. The Generics segment includes 120+ products developed through internal R&D, acquisitions, and licensing. ANI operates three

主要指標

株価: $71.98 (+0.07%)
時価総額: 16億ドル
PER（今期予想）: 7.8
PBR: 2.5
配当利回り: —
52週レンジ: $69.58 – $97.00
業種: Healthcare / Drug Manufacturers - Specialty & Generic
上場: NASDAQ
構成銘柄: —

比較会社: TAK Takeda Pharmaceutical Company Limited、TEVA Teva Pharmaceutical Industries Limited、HLN Haleon plc、ZTS Zoetis Inc.、VTRS Viatris Inc.、ITCI Intra-Cellular Therapies, Inc.、CTLT Catalent, Inc.、ELAN Elanco Animal Health Incorporated

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-06 · 更新: 2026-10-09